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Abstract
Background: Anti-Müllerian hormone (AMH) is a known sensitive biomarker for fertility
and ovarian reserve. The results of in vivo and human studies showed inconsistency
with respect to the relation between AMH and breast cancer.
Objective: To compare the AMH level of young Iranian women with early breast cancer
who have not received any treatment compared to that of healthy women.
Materials and Methods: In this case-control study, 58 breast cancer cases were
recruited from the breast oncology clinic of two university hospitals. They were
diagnosed with an in situ or invasive breast cancer before any anticancer treatment
between August 2018 and April 2019. Healthy controls (n = 58) were selected from
women referred to a gynecologic outpatient clinic without any symptoms of cancer or
infertility. AMH was measured by the AMH enzyme-linked immunosorbent assay kits
in one laboratory.
Results: Final analysis showed that the AMH means of case and control were not
statistically significant (3.36 ± 2.95 vs 3.13 ± 1.79). However, the lower and higher AMH
level categories aremore prevalent in breast cancer compared to the control. Pearson’s
correlation test showed that the AMH level was negatively correlatedwith age (r = -0.44,
p< 0.001). The results of logistic regression analysis considering confounding factors
showed the positive association between breast cancer and lower (Odds Ratio [OR] =
5.98, p = 0.02) and higher quartile of AMH level (OR = 4.95, p = 0.01).
Conclusion: Our results suggest that abnormal AMH level is more frequent in
young breast cancer patients. Further investigation considering AMH determinants is
required.
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1. Introduction
Breast cancer is the most commonly diagnosed
cancer in most regions of the world (1).
Approximately 9.5% of new cases of breast
cancer and 6.7% of breast cancer occur among
women aged < 45 yr (2). A recent study has
shown that the incidence of breast cancer in
young women is increasing (3); the mean age of
the women with breast cancer in Iran is < 50 yr
(4).
Scientists are looking for different biomarkers to
prevent or treat cancers including breast cancer.
One of the researchers’ favorite biomarkers is
Müllerian-inhibiting substance, also known as anti-
Müllerian hormone (AMH). Besides the use of
AMH as a sensitive biomarker for fertility and
ovarian reserve, it serves as a biomarker in
several other conditions (5). For instance, AMH
concentration is used as a reliable marker if at
any time there are minor fluctuations in serum
concentrations during a normal menstrual cycle
(6).
AMH is a member of the transforming
growth factor-β superfamily of the growth and
differentiation response modifiers. Because most
gynecologic tumors originate from Müllerian
duct-derived tissues, and since Müllerian-
inhibiting substance/AMH causes regression
of the Müllerian duct in male embryos, it is
expected to have an inhibiting effect on the
growth of gynecologic tumors (7).
Based on laboratory evidence in cell-line and
mouse models, an inverse association between
AMH level and breast tumor development has
been illustrated (8-11), and it seems that AMH
has a protective effect against breast cancer and
can suppress the growth of mammary tumors.
These findings have led to the suggestion that
AMH could be used in the treatment of breast
and other gynecologic cancers (7). Although
the exact role of AMH in mammary glands is
still unclear, they are possible target tissue of
AMH.
However, different results have been reported
in epidemiological human studies. Some of
them assert that a lower AMH is associated
with a higher rate of breast cancers (12, 13),
while others have shown a positive relationship
between AMH level and breast cancer (14-
17). Since AMH plays a role in regulating
folliculogenesis and the interaction between
AMH and estradiol is not fully understood (18),
the abnormal AMH level may affect estradiol
concentration that will cause breast cancer. A
question that still needs to be investigated is
whether the AMH level before any anticancer
treatment is impacted by cancer itself or abnormal
AMH level is one of the risk factors of breast
cancer?
Because of the inconsistent reported results
about the association between AMH level and
breast cancer, our aim in the present study was
to measure the level of AMH in young Iranian
breast cancer patients and compare it with healthy
controls.
2. Materials and Methods
2.1. Study design and participants
selection
This case-control study was conducted at
two University Hospitals (Cancer Institute and
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Arash Women’s Hospitals) of Tehran University of
Medical Sciences, Tehran, Iran, between August
2018 and April 2019.
Fifty-eight women who recently received
a biopsy-proven diagnosis of breast cancer,
attending the breast oncology clinic as the
case group. Furthermore, they had not received
any anticancer treatment. In the control group
(n = 58) consisted of women attending the
Same Hospitals’ Gynecologic Outpatient Clinic
for routine check-ups and those who had not
reported a previous or current symptoms of
cancer or infertility.
The inclusion criteria for both groups were:
age < 40 yr and regular menstrual cycles
as a defined absence of menopause. The
exclusion criteria were: age > 40, irregular
menstrual cycles, a previous or current
history of infertility, and any symptoms of
menopause.
A trained interviewer gathered individual
information about age, height, weight, education,
marital status, reproductive history, occupation,
history of a disease, and oral contraceptive
use through in person-interview. To evaluate
the antral follicle count (AFC), we offered
transvaginal sonography for all participants if
they agreed. Immunohistochemistry (IHC) was
performed on all breast cancer specimens
and results were recorded as estrogen
receptor (ER), progesterone receptor (PR),
and human epidermal growth factor-2 (HER2)
status.
Body mass index (BMI) was calculated by the
formula of weight divided by height squared
(kg/m2) and categorized based on the WHO
classification (19).
2.2. AMH measurement
Hospital nurses collected 5 ml of blood
samples from the cubital vein. All samples
were stored at room temperature and
transferred to the same laboratory within
2 hr. The laboratory doctor and personnel
were blinded about case and control
groupings.
AMH was measured by the AMH enzyme-
linked immunosorbent assay kits (Beckman
Coulter, AMH gene II assay, Brea, CA, USA).
The limit of detection (LOD) was 0.08 ng/ml
intra-assay and inter-assay variations were
7.7%.
2.3. Sample size calculation
Based on the results of a study (14) and
considering the OR of higher quartile compared
to the reference quartile, we calculated that at
least 44 samples would be required in each
group to detect an association with a power of
80% and α = 0.05 by using Epi Info site (http:
www.cdc.gov/epiinfo). In each group, 60 samples
were recruited for possible losses and further
analysis.
2.4. Ethical considerations
This study was approved by the ethics
committee of Tehran University of Medical
Sciences (IR.TUMS.VCR.REC.1397.693).
Appropriate written informed consent was
obtained from all participants prior to blood
sample collection.
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2.5. Statistical analysis
Data were analyzed using the SPSS software
(version 20, SPSS, Inc., IL, USA). Results are
presented as Mean ± Standard Deviation (SD)
for continuous variables and frequency for
categorical variables. The differences in means
were tested by student’s t test or ANOVA test.
Categorical variables differences were tested by
the Chi-square test (χ2). A two-sided p-value <
0.05 was considered as significant.
Multivariable binary logistic regression
(backward stepwisemethod) was used to estimate
adjusted OR and 95% confidence interval (CI)
for assessing the association between breast
cancer and AMH level. Final statistical model
accounted for age (continuous), age at menarche
(continuous), parity (nulliparous/multiparous),
breastfeeding duration (continuous), and BMI (<
18.5, 18.5-24.9, 25-29.9, ≥ 30 kg/m2) as potential
confounders and AMH quartiles (< 1.41, 1.41-2.66,
2.67-4.45, > 4.45 ng/mL). The second and third
quartiles of the AMH level (1.41-4.45 ng/mL) were
considered as a reference value.
3. Results
The final analysis was performed on the data
collected from 58 women in each group. Table I
presents the Characteristics of cases and controls.
Overall, breast cancer patients had lower single
status women compared to the control group, and
women in the control group were more educated
than those in the case group with borderline
significance (p = 0.07). With respect to the medical
history of the participants, thyroid diseases were
common and other diseases were very rare.
Therefore, self-history of thyroid diseases is
mentioned in Table I, which was more common in
the breast cancer group compared to the control
(12% vs 3.4%, p = 0.08).
AMH was detected in all samples. The
distribution of AMH level was marginally normal
(Kolmogrove-Sminrnove test, p = 0.05). Table
II shows the descriptive value and categorical
AMH levels in both groups. Pearson’s correlation
test showed that the AMH level was negatively
correlated with age (r = -0.45, p < 0.001) (Data
not presented in the table). A comparisons of
the AMH levels between the two groups showed
that the mean concentration of AMH was not
significantly higher in the case group (p = 0.45).
However, a comparison of AMH quartiles
between the two groups showed that the number
of cases belonging to the first and fourth quartiles
was significantly higher than the controls (p <
0.001). AFC in each ovary was evaluated in 57 and
24 of the controls and cases, respectively, and
the average number of antral follicles in ovaries
was similar in both groups (Right: 6.70 ± 3.33 vs
6.71 ± 3.42, p = 0.99; Left: 6.86 ± 3.70 vs 6.54 ±
3.74, p = 0.73). Table III shows that the AMH level
decreased significantly by age increase.
AMH level was significantly higher in HER2-
negative compared with HER2-positive (p = 0.02)
cancers. Meanwhile, AMH level was higher in
ER-positive compared to ER-negative, but not
statistically significant (p = 0.07).
The adjustedORs for breast cancer in relation to
AMH quartiles are shown in table IV. In univariate
analysis, there was a statistically significant
increasing risk with lower and higher quartiles
of AMH concentration. Results were similar after
adjustment for potential confounders.
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Table I. Total characteristics of cases and controls
Variables Breast cancer (n = 58) Control (n = 58) P-value
Age (yr)* 34.88 ± 4.23 34.10 ± 3.28 0.28
BMI (kg/m2)* 25.21 ± 4.24 25.79 ± 4.72 0.49
Age of menarche* 13.39 ± 1.28 13.10 ± 1.17 0.22
Age at first pregnancy* 23.68 ± 5.16 24.46 ± 4.80 0.49
Parity (n)* 1.61 ± 0.88 1.43 ± 0.60 0.30
Lactation period (mo)* 24.02 ± 22.46 16.72 ± 2.63 0.07
Education**
Graduate 24 (41.4) 23 (39.7)
Diploma 14 (24.1) 25 (43.1)
6-11 yr 7 (12.1) 5 (8.6)
< 6 yr 13 (22.4) 5 (8.6)
0.07
Marital status**
Single 12 (20.7) 21 (36.2)
Married 46 (79.3) 37 (63.8)
0.049
Job
Housewife 43 (74.1) 44 (75.9)
Office worker 10 (17.3) 9 (15.5)
Others 5 (8.6) 5 (8.6)
0.97
History of abortion** 17 (29.3) 11 (19) 0.28
OCP use** 19 (32.8) 22 (37.9) 0.70
History of thyroid disease ** 7 (12) 2 (3.4) 0.08
PCOS** 5 (8.6) 9 (15.5) 0.39
BMI category**
< 18.5 1 (1.7) 1 (1.7)
18.5-24.99 27 (46.5) 29 (50)
25-29.99 23 (39.7) 20 (34.5)
≥ 30 7 (12.1) 8 (13.8)
0.95
*Data presented as Mean ± standard deviation. **Data presented as n (%). Continuous variables were compared using
the student’s t test, while categorical variables were examined using Chi-square test. BMI: Body mass index, OCP: Oral
contraceptive pill, PCOS: Polycystic ovarian syndrome
Table II. AMH level and categories in both groups
Breast cancer (n = 58) Control (n = 58) P-value
AMH Level





< 1.41 21 (36.2) 8 (13.8)
1.41-2.66 10 (17.2) 19 (32.8)
2.67-4.45 8 (13.8) 21 (36.2)
> 4.45 19 (32.8) 10 (17.2)
0.001
*Data presented as Mean ± SD. **Data presented as n (%). AMH mean level was compared using the student’s t test and
AMH categories were compared using the Chi-square test. AMH: Anti-Müllerian hormone, SD: Standard deviation, Ln: Natural
logarithm
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Table III. Determinants of AMH level in the studied samples
Variable N Mean ± SD P-value
Age quartiles (yr)
< 31 30 4.76 ± 2.73
32-35 37 3.60 ± 2.31
36-38 27 2.19 ± 1.57
> 38 22 1.88 ± 1.69
< 0.001*
BMI (kg/m2)
< 18.5 2 1.85 ± 0.63
18.5-24.99 56 3.16 ± 2.32
25-29.99 43 3.76 ± 2.71
≥ 30 15 2.29 ± 1.73
0.17*
Lactation period quartile (mo)
No lactation 45 2.92 ± 1.99
1-17 10 4.26 ± 2.93
18-38 32 3.19 ± 2.12
≥ 39 29 3.46 ± 3.10
0.43*
Parity
Nulliparity 36 2.93 ± 2.17
Multiparity 80 3.39 ± 2.53
0.35**
History of abortion
No 88 3.14 ± 2.30
Yes 28 3.59 ± 2.80
0.39**
PCOS
No 102 3.18 ± 2.47
Yes 14 3.76 ± 2.10
0.40**
OCP use
No 75 2.99 ± 2.13
Yes 41 3.72 ± 2.86
0.15**
ER
Positive 26 3.63 ± 3.05
Negative 14 2.20 ± 1.81
0.07**
HER-2
Positive 12 1.74 ± 2.20
Negative 28 3.73 ± 2.77
0.03**
Triple-negative 9 2.34 ± 1.42 -
*P-value refers to the ANOVA-test. **P-value refers to the student’s t test. SD: Standard deviation, BMI: Body mass index, PCOS:
Polycystic ovarian syndrome, OCP: Oral contraceptive pills, ER: Estrogen receptor, HER2: Human epidermal growth factor
receptor 2
Table IV. Unadjusted and adjusted odds ratio from logistic regression for AMH level associated with breast cancer
Variables Cases/controls Unadjusted OR (95% CI) P-value Adjusted OR (95% CI) P-value
AMH level
Q2, 3: 1.41-4.45 18/40 1 (Referent) 1 (Referent)
Q1: < 1.41 21/8 5.83 (2.18-15.64) < 0.001 5.98 (1.42-25.23) 0.02
Q4: > 4.45 19/10 4.22 (1.64-10.88) 0.003 4.95 (1.44-16.98) 0.01
Adjusted OR was calculated considering confounding factors (age, age of menarche, parity, BMI categories, AMH quartiles,
lactation period). OR: Odds ratio, AMH: Anti-Müllerian hormone
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4. Discussion
The serum levels of AMH in young women
with early breast cancer prior to any treatment
was compared to healthy women in the present
study considering confounding factors. We found
a positive association between lower and higher
AMH levels and breast cancer before anticancer
treatment.
Our results were not consistent with preclinical
studies in cell-line and animal models. Those
studies reported that AMH inhibits tumor cell
growth and migration through nuclear factor
kappa-light-chain-enhancer of activated B cells-
mediated pathways, and that after AMH injection,
the ratio of apoptotic cells in murine mammary
tissue increases eightfold (8-11). Therefore, an
inverse association between AMH and breast
tumor development was demonstrated. However,
those models have evaluated the basal-like breast
cancer subtypes, which account for the minority
of breast cancers. As mentioned in Table III,
the AMH level in triple-negative patients is this
study was 2.34 ± 1.42. It seems that AMH
assessment in other subtypes of breast cancer is
necessary.
The present study result shows that the low
level of AMH in young patients is associated with
breast cancer, which has also been confirmed
by other studies (12, 13). McCoy and colleagues
measured the AMH level in premenopausal
women aged 38-50 yr scheduled to undergo
diagnostic breast biopsy to determine the relation
with benign or malignant breast lesions. They
observed a negative association of AMH level with
precancerous and cancerous breast diseases.
However, the sample size of that study was
very low (12). Another epidemiologic study by
Su and co-workers on very young breast cancer
patients (28-44 yr) found a significantly lower AMH
in breast cancer patients in univariate analysis,
and AMH levels that were more frequently
below the detection rates in breast cancer
patients than that of controls. However, in the
multivariablemodel, they didn’t find any significant
difference in the AMH levels between cancerous
patients and healthy women of similar age.
They mentioned that ovarian reserve may be
adversely impacted by cancer status (13). Another
study demonstrated that women with cancer may
have significantly lower AFC before gonadotoxic
therapy compared with healthy women aged
25-40 yr (20). AMH level is correlated with
AFC and this lower AFC and subsequent AMH
level in cancer patients may be explained by
the accelerated follicle loss or a defect in the
recruitment of antral follicles owning to a disease
state.
It is well-known that high breast density is
associated with an increased risk of breast
cancer (21). A recent study examined the relation
of AMH with mammographic breast density.
They found that women with higher AMH
levels had a significantly lower fatty breast
(22). This study supported the hypothesis
of the relationship between AMH levels
and breast cancer. Meanwhile, this study
could support the previous findings which
explained the possible effect of AMH on breast
tissue.
Unlike the aforementioned studies, some
investigations show a positive relationship
between breast cancer and AMH level (14-17).
The first prospective study in premenopausal
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women reported a strong association of AMH (OR
= 9.8, 95% CI: 3.3-28.9) with breast cancer
before the diagnosis, although a weaker
association was observed in breast cancer
patients who were not using oral contraceptive
during blood collection (14). They suggested
that control subjects of their study were
not representative of unaffected women in
the cohort and stated that the association
between AMH and breast cancer could be
biased.
A large-scale study that evaluated the AMH
level and risk of breast cancer in 10 prospective
cohorts reported a positive relationship between
breast cancer and AMH level (17). However,
that study sample population consisted of
premenopausal women of any age at the
time of blood donation. Further, two recent
prospective studies observed a strong positive
association between increasing categories of
AMH and breast cancer. In these two studies, the
association was weaker among younger women
and neither study reported the menopausal status
at the time of diagnosis (15, 16). In Elaissen and
colleagues study, control groups were selected
without considering menopausal status, and
they allowed postmenopausal women among
controls; this caused a higher estimation of the
association between breast cancer and AMH (16).
Since Rustamov and co-workers have shown that
AMH level is reproducible over time like other
biologic variables (23), it should be considered
especially in the cohort study which evaluated
the hormone level after many years of sample
collection.
Our results showed that the AMH level is higher
in the PCOS group (Table III) as we expected
based on previous study (24), although it was
not statistically significant. Blumenfeld (25) has
discussed the recent study by Ge and colleagues
which has found that the breast cancer has a
positive relation with AMH level (17). Blumenfeld
has mentioned that the positive relation of breast
cancer with AMH level may be due to a higher
prevalence of PCOS patients in the high AMH-
level group (25). His argument is based on the
possible relationship between breast cancer and
PCOS, which of course has been rejected in the
recently published systematic review and meta-
analysis (26, 27).
According to IHC of breast cancer patients,
AMH level was higher in ER-positive (p = 0.07)
and Her2-negative tumors (p = 0.03) (Table III).
Although our results require further investigation
due to the small sample size and lack of access to
IHC of all patients, Ge and co-authors study also
confirmed the increasing trend of AMH for tumors
positive for both estrogen and progesterone
receptors (17). It seems that further evaluation of
AMH level in subtypes of breast cancer is needed
for appropriate fertility preservation counseling.
A recent study showed that breast cancer
patients with BRCA mutation have significantly
lower serum AMH levels and recommended that
fertility preservation should be considered more
aggressively in these patients (28). Therefore,
for the accurate evaluation of the association
between AMH level and breast cancer, BRCA
mutation assessment is necessary.
The present study has some advantages.
Based on our knowledge, this is the first
evaluation of the AMH level in young Iranian
breast cancer patients. In this study, we measured
AMH levels for 2 hours after sampling and used
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the AMH Gene II assay kit for measurement,
which is highly specific and reproducible (29).
Limitation
The first limitation of the current study is that
since the AMH level was evaluated after a breast
cancer diagnosis, it might not reflect the AMH level
before cancer development. Another limitation
might the small sample size of the study compared
with large cohorts.
5. Conclusion
In conclusion, we found the lower and higher
AMH level categories are more prevalent in
young breast cancer patients who were in
premenopausal status and didn’t receive any
cytotoxic treatment. Further studies are necessary
with a larger sample size, considering age,
menopausal status, oral contraceptive use, and
previous history of other diseases such as PCOS
as well as genetic assessment for BRCA mutation.
As young women are more likely to benefit
from preventive drug intervention, individual risk
assessment is particularly valuable in young
women and can encourage them to pursue
screening for early detection of breast cancer, or
offer them new biomarker-based treatments.
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